Batgi, H. Et Al. 2021. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience. Turkish Journal of Medical Sciences , vol.51, no.2 , 685-692.

Batgi, H., Basci, S., Dal, M. S., Kizil Çakar, M., Uncu Ulu, B., Yigenoglu, T. N., ... Özcan, N.(2021). Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience. Turkish Journal of Medical Sciences , vol.51, no.2, 685-692.

Batgi, SEMİH Et Al. "Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience," Turkish Journal of Medical Sciences , vol.51, no.2, 685-692, 2021

Batgi, SEMİH Et Al. "Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience." Turkish Journal of Medical Sciences , vol.51, no.2, pp.685-692, 2021

Batgi, H. Et Al. (2021) . "Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience." Turkish Journal of Medical Sciences , vol.51, no.2, pp.685-692.

@article{article, author={SEMİH BAŞCI Et Al. }, title={Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: A single center experience}, journal={Turkish Journal of Medical Sciences}, year=2021, pages={685-692} }